Mauricio González-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mauricio González-García has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Arturo Torres-Duque
CINEUMO, Respiratory Research Center, Fundación Neumológica Colombiana, Bogotá, Colombia
22 shared publications - Alejandro Casas
Fundacion Neumologica Colombiana
5 shared publications - Claudia Jaramillo
Fundación Clínica Shaio
5 shared publications Dario Maldonado
Pulmonary Function Testing Laboratory, Fundación Neumológica Colombiana, Bogotá, Colombia
5 shared publications- Elida Duenas-Meza
Fundacion Neumologica Colombiana Bogotà Colombia
5 shared publications - Margarita Barrero
Pulmonary Function Testing Laboratory, Fundación Neumológica Colombiana, Bogotá, Colombia
5 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1956566
Differences in pulse oximetry saturation from sea level to high altitude among subjects with and without respiratory disease. A population-based, cross-sectional study
Introduction: Oxygen saturation (SpO 2 ) is used to detect hypoxemia and guide oxygen therapy, but its interpretation varies with altitude, age, and lung disease. Although >500 million people live at ≥1,500 m, population-based data comparing SpO 2 across altitudes in adults with and without chronic respiratory disease are scarce. We aimed to compare SpO 2 between these groups from sea level to 3,030 m, identify factors associated with SpO 2 , and describe SpO 2 by altitude and age in adults without respiratory disease. We hypothesized that SpO 2 would be lower in participants with respiratory disease, with differences increasing with altitude. Methods: PREPOCOL II is a population-based, cross-sectional study with a probabilistic, two-stage, clustered sampling design to estimate the prevalence and risk factors for respiratory disease among adults ≥40 years in Colombian cities at different altitudes (18-3030 m). All participants completed a standardized questionnaire, spirometry, and SpO 2 measurement. Participants with respiratory disease (RDP), including chronic obstructive pulmonary disease, asthma, chronic bronchitis, obstructive sleep apnea, and interstitial lung disease, were compared with controls using Mann-Whitney and Kruskal-Wallis tests, multivariable linear regression, and comparisons of altitude coefficients between groups. Results: A total of 1146 RDP and 4613 controls were included. RDP were older, and had lower BMI and lung function. SpO 2 was lower in RDP than in controls at all altitudes and decreased in both groups as altitude and age increased (p2 (standardized β −0.69 in controls and −0.71 in RDP), followed by age and BMI (and FEV 1 in RDP). The decrease in SpO 2 per unit of altitude was larger in RDP (B −1.15 vs. −0.80; difference p2 was lower in RDP than in controls. SpO 2 decreased with altitude and age in both groups, with altitude being the variable most strongly associated with SpO 2 . SpO 2 values should be interpreted in relation to specific altitude and age. In RDP, the lower SpO 2 was most evident at altitudes of ~1,500 m and above.
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1956566
Open AccessDifferences in pulse oximetry saturation from sea level to high altitude among subjects with and without respiratory disease. A population-based, cross-sectional study
Introduction: Oxygen saturation (SpO 2 ) is used to detect hypoxemia and guide oxygen therapy, but its interpretation varies with altitude, age, and lung disease. Although >500 million people live at ≥1,500 m, population-based data comparing SpO 2 across altitudes in adults with and without chronic respiratory disease are scarce. We aimed to compare SpO 2 between these groups from sea level to 3,030 m, identify factors associated with SpO 2 , and describe SpO 2 by altitude and age in adults without respiratory disease. We hypothesized that SpO 2 would be lower in participants with respiratory disease, with differences increasing with altitude. Methods: PREPOCOL II is a population-based, cross-sectional study with a probabilistic, two-stage, clustered sampling design to estimate the prevalence and risk factors for respiratory disease among adults ≥40 years in Colombian cities at different altitudes (18-3030 m). All participants completed a standardized questionnaire, spirometry, and SpO 2 measurement. Participants with respiratory disease (RDP), including chronic obstructive pulmonary disease, asthma, chronic bronchitis, obstructive sleep apnea, and interstitial lung disease, were compared with controls using Mann-Whitney and Kruskal-Wallis tests, multivariable linear regression, and comparisons of altitude coefficients between groups. Results: A total of 1146 RDP and 4613 controls were included. RDP were older, and had lower BMI and lung function. SpO 2 was lower in RDP than in controls at all altitudes and decreased in both groups as altitude and age increased (p2 (standardized β −0.69 in controls and −0.71 in RDP), followed by age and BMI (and FEV 1 in RDP). The decrease in SpO 2 per unit of altitude was larger in RDP (B −1.15 vs. −0.80; difference p2 was lower in RDP than in controls. SpO 2 decreased with altitude and age in both groups, with altitude being the variable most strongly associated with SpO 2 . SpO 2 values should be interpreted in relation to specific altitude and age. In RDP, the lower SpO 2 was most evident at altitudes of ~1,500 m and above.
- Open Access
- 1 September 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-16
Chronic Obstructive Pulmonary Disease and Multimorbidity: Insights from a National Claims Administrative Database
Purpose: To estimate the prevalence of diagnosed chronic obstructive pulmonary disease (COPD) and characterize the frequency and distribution of multimorbidity among individuals with and without COPD in Colombia’s contributory health system. Patients and Methods: We conducted a cross-sectional study using administrative healthcare data from the Capitation Unit Sufficiency Database (Unidad de Pago por Capitación, UPC) and the Unique Enrollees Database (Base de Datos Única de Afiliados, BDUA). An electronic algorithm was used to identify individuals with a COPD diagnosis and to estimate diagnosed COPD prevalence among all affiliates during 2018– 2019. We also estimated the prevalence of selected health conditions among individuals with and without COPD. Differences between groups were assessed in two steps. First, standardized mean differences (SMDs) were calculated for prevalence estimates. Second, conditions with SMDs of approximately 0.1 or greater were further evaluated using prevalence ratios (PRs) adjusted for sex, region, age, insurer, and prior healthcare service utilization estimated with Poisson regression with robust variance and 95% confidence intervals. Results: The study included 6,865,420 individuals. The nationwide prevalence of diagnosed COPD was 2.21% (95% CI, 2.20– 2.22), with the highest prevalence observed in the Central region (2.77%; 95% CI, 2.74– 2.79). In adjusted analyses, several conditions were more prevalent among individuals with COPD, including asthma (PR = 3.88; 95% CI, 2.88– 5.23), sleep apnea (PR = 2.62; 95% CI, 2.05– 3.35), heart failure (PR = 1.89; 95% CI, 1.29– 2.78), ischemic heart disease (PR = 1.60; 95% CI, 1.26– 2.03), hypertension (PR = 1.08; 95% CI, 1.02– 1.15), and osteoporosis (PR = 2.34; 95% CI, 1.52– 3.58), among others, were more prevalent among individuals with COPD. Lung cancer (PR = 6.41; 95% CI, 5.89– 6.97) and breast cancer (PR = 1.17; 95% CI, 1.08– 1.25) were also more prevalent in this population. Conclusion: Individuals with diagnosed COPD in Colombia’s contributory health system had a substantial burden of multimorbidity, particularly respiratory and cardiovascular conditions. These findings support interdisciplinary care models and locally tailored strategies to address regional differences in diagnosed COPD.
- 1 September 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-16
Open AccessChronic Obstructive Pulmonary Disease and Multimorbidity: Insights from a National Claims Administrative Database
Purpose: To estimate the prevalence of diagnosed chronic obstructive pulmonary disease (COPD) and characterize the frequency and distribution of multimorbidity among individuals with and without COPD in Colombia’s contributory health system. Patients and Methods: We conducted a cross-sectional study using administrative healthcare data from the Capitation Unit Sufficiency Database (Unidad de Pago por Capitación, UPC) and the Unique Enrollees Database (Base de Datos Única de Afiliados, BDUA). An electronic algorithm was used to identify individuals with a COPD diagnosis and to estimate diagnosed COPD prevalence among all affiliates during 2018– 2019. We also estimated the prevalence of selected health conditions among individuals with and without COPD. Differences between groups were assessed in two steps. First, standardized mean differences (SMDs) were calculated for prevalence estimates. Second, conditions with SMDs of approximately 0.1 or greater were further evaluated using prevalence ratios (PRs) adjusted for sex, region, age, insurer, and prior healthcare service utilization estimated with Poisson regression with robust variance and 95% confidence intervals. Results: The study included 6,865,420 individuals. The nationwide prevalence of diagnosed COPD was 2.21% (95% CI, 2.20– 2.22), with the highest prevalence observed in the Central region (2.77%; 95% CI, 2.74– 2.79). In adjusted analyses, several conditions were more prevalent among individuals with COPD, including asthma (PR = 3.88; 95% CI, 2.88– 5.23), sleep apnea (PR = 2.62; 95% CI, 2.05– 3.35), heart failure (PR = 1.89; 95% CI, 1.29– 2.78), ischemic heart disease (PR = 1.60; 95% CI, 1.26– 2.03), hypertension (PR = 1.08; 95% CI, 1.02– 1.15), and osteoporosis (PR = 2.34; 95% CI, 1.52– 3.58), among others, were more prevalent among individuals with COPD. Lung cancer (PR = 6.41; 95% CI, 5.89– 6.97) and breast cancer (PR = 1.17; 95% CI, 1.08– 1.25) were also more prevalent in this population. Conclusion: Individuals with diagnosed COPD in Colombia’s contributory health system had a substantial burden of multimorbidity, particularly respiratory and cardiovascular conditions. These findings support interdisciplinary care models and locally tailored strategies to address regional differences in diagnosed COPD.
- Open Access
- 15 July 2026
- Published by Asociacion Colombiana de Neumologia y Cirugia de Torax in Revista Colombiana de Neumología
- Vol. 38 (1Supp1) , 1-85
Consenso Colombiano de Uso de Ventilación Mecánica no invasiva en pacientes con Enfermedades neuromusculares
Introducción: la ventilación no invasiva (VNI) ha demostrado ser un método eficaz, simple y de bajo costo para el tratamiento de la falla respiratoria hipercápnica crónica. Sin embargo, su evidencia clínica ha sido descrita principalmente en pacientes con enfermedad pulmonar obstructiva crónica (EPOC), hipoventilación, obesidad y edema pulmonar cardiogénico, con limitaciones importantes reportadas en las publicaciones de pacientes con enfermedad neuromuscular (ENM). Aunque existe la necesidad de realizar grandes estudios aleatorizados en este grupo de pacientes, la literatura y la experiencia clínica actual soportan de manera inequívoca el beneficio de la VNI en mejorar la calidad de vida, disminuir el riesgo de infecciones respiratorias e impactar la mortalidad en algunos grupos de pacientes. El objetivo de este consenso es realizar recomendaciones de expertos, basadas en la evidencia científica disponible y la experiencia adquirida en los pacientes con ENM. Metodología: se realizó una búsqueda estructurada basada en preguntas PICOT en diferentes bases de datos, incluyendo literatura publicada entre enero de 1992 y febrero de 2025. La selección de estudios fue realizada por revisores independientes y las recomendaciones se elaboraron con base en la estrategia GRADE. El acuerdo entre expertos se definió mediante metodología Delphi, considerando consenso con más del 75 % de los votos y recomendación muy fuerte con más del 90 %. Resultados: a partir de la evidencia identificada y del consenso de expertos, se formularon 57 recomendaciones para el uso de VNI en pacientes con falla ventilatoria crónica secundaria a ENM. Conclusiones: este consenso proporciona recomendaciones basadas en evidencia y en la experiencia de expertos para el uso de VNI en pacientes con ENM. A pesar de la limitada disponibilidad de estudios aleatorizados de gran tamaño, la evidencia actual apoya su beneficio en pacientes seleccionados y respalda su incorporación en la práctica clínica.
- 15 July 2026
- Published by Asociacion Colombiana de Neumologia y Cirugia de Torax in Revista Colombiana de Neumología
- Vol. 38 (1Supp1) , 1-85
Open AccessConsenso Colombiano de Uso de Ventilación Mecánica no invasiva en pacientes con Enfermedades neuromusculares
Introducción: la ventilación no invasiva (VNI) ha demostrado ser un método eficaz, simple y de bajo costo para el tratamiento de la falla respiratoria hipercápnica crónica. Sin embargo, su evidencia clínica ha sido descrita principalmente en pacientes con enfermedad pulmonar obstructiva crónica (EPOC), hipoventilación, obesidad y edema pulmonar cardiogénico, con limitaciones importantes reportadas en las publicaciones de pacientes con enfermedad neuromuscular (ENM). Aunque existe la necesidad de realizar grandes estudios aleatorizados en este grupo de pacientes, la literatura y la experiencia clínica actual soportan de manera inequívoca el beneficio de la VNI en mejorar la calidad de vida, disminuir el riesgo de infecciones respiratorias e impactar la mortalidad en algunos grupos de pacientes. El objetivo de este consenso es realizar recomendaciones de expertos, basadas en la evidencia científica disponible y la experiencia adquirida en los pacientes con ENM. Metodología: se realizó una búsqueda estructurada basada en preguntas PICOT en diferentes bases de datos, incluyendo literatura publicada entre enero de 1992 y febrero de 2025. La selección de estudios fue realizada por revisores independientes y las recomendaciones se elaboraron con base en la estrategia GRADE. El acuerdo entre expertos se definió mediante metodología Delphi, considerando consenso con más del 75 % de los votos y recomendación muy fuerte con más del 90 %. Resultados: a partir de la evidencia identificada y del consenso de expertos, se formularon 57 recomendaciones para el uso de VNI en pacientes con falla ventilatoria crónica secundaria a ENM. Conclusiones: este consenso proporciona recomendaciones basadas en evidencia y en la experiencia de expertos para el uso de VNI en pacientes con ENM. A pesar de la limitada disponibilidad de estudios aleatorizados de gran tamaño, la evidencia actual apoya su beneficio en pacientes seleccionados y respalda su incorporación en la práctica clínica.
- Open Access
- 17 June 2026
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 23
Exposure to indoor wood smoke, rather than hypoxemia, is a risk factor for cognitive impairment in COPD patients living at high altitude
Background: In the general population without COPD, indoor air pollution from biomass is a causal factor of cognitive impairment (CI). CI is also common in patients with tobacco smoke COPD and has been associated with hypoxemia and cardiovascular comorbidities. CI and its risk factors have not been evaluated in COPD patients living at high altitude, who experience greater hypoxemia and frequent exposure to wood smoke. Methods: Patients with COPD residing at high altitude with FEV1/FVC <0,70 and COPD risk factors (wood smoke, Tobacco smoke or combined exposure). Measurement of the Mini-Mental State Examination to assess CI, educational level, comorbidities, exacerbations, arterial blood gases, diffusion (DLCO), and 6-min walk test (6MWT). Comparisons between groups with and without CI using the X2 test and unpaired t-test. Logistic regression with odds ratio (OR) calculation was used to evaluate the association of CI with the variables of interest. Results: In the 199 patients included, 16.1% had CI, the majority with mild involvement (68.8%). Those with CI had more frequent exposure to wood smoke (p<0.001), older age (p=0.017), lower educational level, PaO2 (p=0.032), DLCO (p=0.036), and fewer meters in the 6MWT (p=0.007), with no differences in sex, severity of obstruction or comorbidities. Adjusting for the other variables, exposure to wood smoke was associated with CI [OR and 95% CI: 4.82 (1.62-14.33). Conclusions: In patients with mild to moderate COPD living at high altitude, regardless of hypoxemia, age, educational level, comorbidities, and lung function, exposure to wood smoke was associated with CI.
- 17 June 2026
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 23
Open AccessExposure to indoor wood smoke, rather than hypoxemia, is a risk factor for cognitive impairment in COPD patients living at high altitude
Background: In the general population without COPD, indoor air pollution from biomass is a causal factor of cognitive impairment (CI). CI is also common in patients with tobacco smoke COPD and has been associated with hypoxemia and cardiovascular comorbidities. CI and its risk factors have not been evaluated in COPD patients living at high altitude, who experience greater hypoxemia and frequent exposure to wood smoke. Methods: Patients with COPD residing at high altitude with FEV1/FVC <0,70 and COPD risk factors (wood smoke, Tobacco smoke or combined exposure). Measurement of the Mini-Mental State Examination to assess CI, educational level, comorbidities, exacerbations, arterial blood gases, diffusion (DLCO), and 6-min walk test (6MWT). Comparisons between groups with and without CI using the X2 test and unpaired t-test. Logistic regression with odds ratio (OR) calculation was used to evaluate the association of CI with the variables of interest. Results: In the 199 patients included, 16.1% had CI, the majority with mild involvement (68.8%). Those with CI had more frequent exposure to wood smoke (p<0.001), older age (p=0.017), lower educational level, PaO2 (p=0.032), DLCO (p=0.036), and fewer meters in the 6MWT (p=0.007), with no differences in sex, severity of obstruction or comorbidities. Adjusting for the other variables, exposure to wood smoke was associated with CI [OR and 95% CI: 4.82 (1.62-14.33). Conclusions: In patients with mild to moderate COPD living at high altitude, regardless of hypoxemia, age, educational level, comorbidities, and lung function, exposure to wood smoke was associated with CI.
- Open Access
- 3 March 2026
- Published by Universidad Pontificia Bolivariana in Medicina UPB
- Vol. 45 (1) , 21-29
Evaluación de citoquinas circulantes en pacientes con fibrosis pulmonar idiopática en Bogotá
Objective: To identify changes in cytokine concentration in the plasma of patients with IPF and healthy controls residing in Bogotá. Methods: Peripheral blood samples were taken from 13 patients over 60 years old with a diagnosis of IPF and 13 healthy counterparts. Plasma separation was performed and stored at -20°C. Cytokines were measured using the Human TH1/TH2 Cytometric Bead Array (CBA). This work was approved by the ethics and research committee of the Fundación Neumológica Colombiana. Results: Patients with Idiopathic Pulmonary Fibrosis (IPF) showed increased levels of cytokines such us IL-4, INF-γ and IL-6 compared to healthy older adults. Conclusions: Inflammaging has been associated with the development and coexistence of multiple non-communicable chronic diseases that have a higher incidence after the age of 65. The involvement of adaptive immunity in the pathogenesis of IPF has been described as an imbalance in the Th1/Th2 lymphocyte response. IL-4 stimulation favors the phenotypic shift to M2 macrophages and Th2 cells, along with the promotion of pro-fibrotic environments by Innate lymphoid cells type 2 (ILC-2).
- 3 March 2026
- Published by Universidad Pontificia Bolivariana in Medicina UPB
- Vol. 45 (1) , 21-29
Open AccessEvaluación de citoquinas circulantes en pacientes con fibrosis pulmonar idiopática en Bogotá
Objective: To identify changes in cytokine concentration in the plasma of patients with IPF and healthy controls residing in Bogotá. Methods: Peripheral blood samples were taken from 13 patients over 60 years old with a diagnosis of IPF and 13 healthy counterparts. Plasma separation was performed and stored at -20°C. Cytokines were measured using the Human TH1/TH2 Cytometric Bead Array (CBA). This work was approved by the ethics and research committee of the Fundación Neumológica Colombiana. Results: Patients with Idiopathic Pulmonary Fibrosis (IPF) showed increased levels of cytokines such us IL-4, INF-γ and IL-6 compared to healthy older adults. Conclusions: Inflammaging has been associated with the development and coexistence of multiple non-communicable chronic diseases that have a higher incidence after the age of 65. The involvement of adaptive immunity in the pathogenesis of IPF has been described as an imbalance in the Th1/Th2 lymphocyte response. IL-4 stimulation favors the phenotypic shift to M2 macrophages and Th2 cells, along with the promotion of pro-fibrotic environments by Innate lymphoid cells type 2 (ILC-2).
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2026 (1) , 6769563
Association Between Pulmonary Function Parameters and Apnea Hypopnea Index in Asthmatic Children Living at High Altitude
Introduction: Obstructive sleep apnea (OSA) has been associated with poorer asthma outcomes in children, including reduced disease control and a greater risk of exacerbation. However, little is known about the relationship between sleep‐disordered breathing severity and pulmonary function in pediatric patients residing at high altitude. Methods: We conducted a cross‐sectional study including children aged 3–12 years with physician‐diagnosed asthma who underwent overnight polysomnography at a referral center in Bogotá, Colombia (2640 m above sea level), between 2012 and 2017. Clinical characteristics, spirometric measurements, oscillometry parameters, and polysomnographic variables were collected and analyzed. Associations between pulmonary function indices and apnea–hypopnea measures were evaluated using Spearman correlation analysis. Results: Sixty‐four children were included, of whom 59.4% had moderate‐to‐severe asthma and 59.4% had uncontrolled disease. In oscillometry, airway resistance at 5 Hz (R5) demonstrated an inverse correlation with AHI before bronchodilator administration ( r = −0.440, p < 0.05) and after bronchodilator administration ( r = −0.491, p < 0.05). Similar inverse correlations were observed between R5 and OAHI. Among spirometric variables, postbronchodilator FEV1 was negatively correlated with OAHI ( r = −0.329, p < 0.05). No significant associations were found between OSA severity and asthma severity, body mass index, or nocturnal oxygen saturation. Conclusions: Our findings revealed an association between the AHI and VEF1 in asthmatic children residing in a tropical city at high altitude. However, the results regarding the relationship between AHI and R5 were contradictory.
- 1 January 2026
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2026 (1) , 6769563
Open AccessAssociation Between Pulmonary Function Parameters and Apnea Hypopnea Index in Asthmatic Children Living at High Altitude
Introduction: Obstructive sleep apnea (OSA) has been associated with poorer asthma outcomes in children, including reduced disease control and a greater risk of exacerbation. However, little is known about the relationship between sleep‐disordered breathing severity and pulmonary function in pediatric patients residing at high altitude. Methods: We conducted a cross‐sectional study including children aged 3–12 years with physician‐diagnosed asthma who underwent overnight polysomnography at a referral center in Bogotá, Colombia (2640 m above sea level), between 2012 and 2017. Clinical characteristics, spirometric measurements, oscillometry parameters, and polysomnographic variables were collected and analyzed. Associations between pulmonary function indices and apnea–hypopnea measures were evaluated using Spearman correlation analysis. Results: Sixty‐four children were included, of whom 59.4% had moderate‐to‐severe asthma and 59.4% had uncontrolled disease. In oscillometry, airway resistance at 5 Hz (R5) demonstrated an inverse correlation with AHI before bronchodilator administration ( r = −0.440, p < 0.05) and after bronchodilator administration ( r = −0.491, p < 0.05). Similar inverse correlations were observed between R5 and OAHI. Among spirometric variables, postbronchodilator FEV1 was negatively correlated with OAHI ( r = −0.329, p < 0.05). No significant associations were found between OSA severity and asthma severity, body mass index, or nocturnal oxygen saturation. Conclusions: Our findings revealed an association between the AHI and VEF1 in asthmatic children residing in a tropical city at high altitude. However, the results regarding the relationship between AHI and R5 were contradictory.
- Open Access
- 1 January 2026
- Published by Wiley in Pulmonary Medicine
- Vol. 2026 (1) , e2867844
Survival and Hemodynamic Effects of Parenteral Prostanoids in High‐Altitude Group 1 Pulmonary Hypertension: A Retrospective Cohort Study
Background: In Latin America, the evidence regarding the use of prostanoids at high altitude in patients with Group 1 pulmonary hypertension (PH‐1) is limited. Therefore, it is essential to describe the clinical characteristics and outcomes associated with prostanoid treatment in this population. Methods: This retrospective study involved patients with PH‐1. Hemodynamic and clinical variables were compared before the initiation of prostanoids and during clinical follow‐up. Overall survival was analyzed using Kaplan–Meier estimation, with survival rates calculated at 3 and 5 years. The strength of the association for each variable concerning the proposed outcomes was estimated by calculating the odds ratio (OR). Results: The study included 55 patients (mean age 34.6 ± 10.3 years), 83.6% women, all receiving triple combination therapy with endothelin receptor antagonists (ERAs), phosphodiesterase Type 5 inhibitors, and parenteral prostacyclin analogues. Idiopathic pulmonary arterial hypertension was present in 62%, and 60% were classified as intermediate risk at baseline. Median time from PH‐1 diagnosis to prostacyclin initiation was 8.96 months (IQR 1.88–41.42). At 1 year, complete follow‐up data were available for 49 patients. St. George′s Respiratory Questionnaire scores improved significantly from 49.0 to 36.5 at 1 year and 31.5 at the last follow‐up ( p < 0.001). Cardiac index increased from 2.24 to 2.96 L/min/m 2 at 1 year ( p < 0.001), whereas mixed venous oxygen saturation improved significantly. In survivors, the 6‐min walk test distance increased by 53.5 m, and pulmonary vascular resistance decreased by 3.8 WU. Diffusing capacity for carbon monoxide (DLCO) < 25% was associated with an OR of 7.35 (95% CI: 1.28–41.92; p = 0.015), and tricuspid annular plane systolic excursion to pulmonary artery systolic pressure ratio (TAPSE/PASP) < 0.10 mm/mmHg had an OR of 5.78 (95% CI: 0.64–52.03; p = 0.088). Female sex had an OR of 0.13 (95% CI: 0.02–0.78; p = 0.016). Three‐ and five‐year survival rates were 87.2% and 78.1%, respectively. Conclusion: Parenteral prostanoids in patients with PH‐1 demonstrate improvements in hemodynamic variables during clinical follow‐up. A DLCO < 25% and a TAPSE/PASP < 0.10 mm/mmHg were associated with an increased risk of mortality, whereas female sex was identified as a protective factor.
- 1 January 2026
- Published by Wiley in Pulmonary Medicine
- Vol. 2026 (1) , e2867844
Open AccessSurvival and Hemodynamic Effects of Parenteral Prostanoids in High‐Altitude Group 1 Pulmonary Hypertension: A Retrospective Cohort Study
Background: In Latin America, the evidence regarding the use of prostanoids at high altitude in patients with Group 1 pulmonary hypertension (PH‐1) is limited. Therefore, it is essential to describe the clinical characteristics and outcomes associated with prostanoid treatment in this population. Methods: This retrospective study involved patients with PH‐1. Hemodynamic and clinical variables were compared before the initiation of prostanoids and during clinical follow‐up. Overall survival was analyzed using Kaplan–Meier estimation, with survival rates calculated at 3 and 5 years. The strength of the association for each variable concerning the proposed outcomes was estimated by calculating the odds ratio (OR). Results: The study included 55 patients (mean age 34.6 ± 10.3 years), 83.6% women, all receiving triple combination therapy with endothelin receptor antagonists (ERAs), phosphodiesterase Type 5 inhibitors, and parenteral prostacyclin analogues. Idiopathic pulmonary arterial hypertension was present in 62%, and 60% were classified as intermediate risk at baseline. Median time from PH‐1 diagnosis to prostacyclin initiation was 8.96 months (IQR 1.88–41.42). At 1 year, complete follow‐up data were available for 49 patients. St. George′s Respiratory Questionnaire scores improved significantly from 49.0 to 36.5 at 1 year and 31.5 at the last follow‐up ( p < 0.001). Cardiac index increased from 2.24 to 2.96 L/min/m 2 at 1 year ( p < 0.001), whereas mixed venous oxygen saturation improved significantly. In survivors, the 6‐min walk test distance increased by 53.5 m, and pulmonary vascular resistance decreased by 3.8 WU. Diffusing capacity for carbon monoxide (DLCO) < 25% was associated with an OR of 7.35 (95% CI: 1.28–41.92; p = 0.015), and tricuspid annular plane systolic excursion to pulmonary artery systolic pressure ratio (TAPSE/PASP) < 0.10 mm/mmHg had an OR of 5.78 (95% CI: 0.64–52.03; p = 0.088). Female sex had an OR of 0.13 (95% CI: 0.02–0.78; p = 0.016). Three‐ and five‐year survival rates were 87.2% and 78.1%, respectively. Conclusion: Parenteral prostanoids in patients with PH‐1 demonstrate improvements in hemodynamic variables during clinical follow‐up. A DLCO < 25% and a TAPSE/PASP < 0.10 mm/mmHg were associated with an increased risk of mortality, whereas female sex was identified as a protective factor.
- Open Access
- 30 May 2025
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 45 (2) , 277-285
Asthma underdiagnosis in children: A school-based screening in a low socioeconomic status population
Introduction. International asthma management and prevention recommendations emphasize the importance of early and accurate diagnosis and adequate disease control. However, these aspects remain a serious concern, especially in children with low socioeconomic status.Objective. To describe asthma prevalence, underdiagnosis, severity, and control among children with low socioeconomic status in Bogotá, Colombia.Materials and methods. We conducted a cross-sectional study using the International Study of Asthma and Allergies Questionnaire in children aged 7-11 in two public schools. The children with affirmative answers in the questionnaire were evaluated clinically and functionally at the mobile health care unit. Asthma prevalence, underdiagnosis, control level, severity, and patients’ quality of life were assessed with validated instruments.Results. We screened 920 schoolchildren with an age of 9.5 ± 1.1; 186 were evaluated clinically and functionally by spirometry, and 122 of them were diagnosed with asthma (17.2%). Underdiagnosis was 68%. Most patients had moderate and severe asthma, and 90% were cases of not well or very poorly controlled asthma.Conclusions. Screening children in school settings is a suitable strategy for detecting asthma and reducing underdiagnosis in communities with low socioeconomic status and limited access to health care services. The asthma underdiagnosis and poor disease control were high.
- 30 May 2025
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 45 (2) , 277-285
Open AccessAsthma underdiagnosis in children: A school-based screening in a low socioeconomic status population
Introduction. International asthma management and prevention recommendations emphasize the importance of early and accurate diagnosis and adequate disease control. However, these aspects remain a serious concern, especially in children with low socioeconomic status.Objective. To describe asthma prevalence, underdiagnosis, severity, and control among children with low socioeconomic status in Bogotá, Colombia.Materials and methods. We conducted a cross-sectional study using the International Study of Asthma and Allergies Questionnaire in children aged 7-11 in two public schools. The children with affirmative answers in the questionnaire were evaluated clinically and functionally at the mobile health care unit. Asthma prevalence, underdiagnosis, control level, severity, and patients’ quality of life were assessed with validated instruments.Results. We screened 920 schoolchildren with an age of 9.5 ± 1.1; 186 were evaluated clinically and functionally by spirometry, and 122 of them were diagnosed with asthma (17.2%). Underdiagnosis was 68%. Most patients had moderate and severe asthma, and 90% were cases of not well or very poorly controlled asthma.Conclusions. Screening children in school settings is a suitable strategy for detecting asthma and reducing underdiagnosis in communities with low socioeconomic status and limited access to health care services. The asthma underdiagnosis and poor disease control were high.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 1161-1174
Plasma Levels of CXCL9 and MCP-3 are Increased in Asthma-COPD Overlap (ACO) Patients
Purpose: Asthma and chronic obstructive pulmonary disease overlap patients (ACO) have more exacerbations and a worse prognosis than pure asthma or COPD, and it is of great interest to identify differential biomarkers of ACO. We compared blood eosinophil counts, plasma IgE and protein levels among patients with asthma, ACO, COPD, and healthy subjects to identify those associated with ACO. Patients and Methods: 397 adults (age 40– 90 years) were recruited from two Colombian cities: asthma (n=123), COPD (n=100), ACO (n=74) and healthy control (HC, n=100). Plasma protein levels were measured using the Proximity Extension Assay (Olink Proteomics). Results: There were no differences in blood eosinophil counts between the patient groups. Total and specified IgE levels were higher in patients with ACO than in those with COPD. Ten plasma proteins showed significant differences between the patients with ACO and HC. In patients above 60 years old, CXCL9 discriminates ACO from asthma patients with AUC 0.73 (0.63– 0.82, DeLong test p=0.007), and in patients below 60 years old, MCP-3 discriminates ACO from COPD patients with AUC 0.84 (0.62– 1.0, DeLong test p=0.006). CUB domain-containing protein 1 (CDCP1) levels (OR, 0.47; p=0.008) and age > 60 years (OR, 0.25; p=0.001) were negatively associated with ACO. Conclusion: CXCL9 levels could be used to discriminate ACO from asthma patients and MCP-3 to discriminate ACO from COPD. Protein inflammatory signatures in plasma of ACO patients were similar to the COPD group. This study revealed novel biomarkers that may help characterize patients with ACO.
- 1 April 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 1161-1174
Open AccessPlasma Levels of CXCL9 and MCP-3 are Increased in Asthma-COPD Overlap (ACO) Patients
Purpose: Asthma and chronic obstructive pulmonary disease overlap patients (ACO) have more exacerbations and a worse prognosis than pure asthma or COPD, and it is of great interest to identify differential biomarkers of ACO. We compared blood eosinophil counts, plasma IgE and protein levels among patients with asthma, ACO, COPD, and healthy subjects to identify those associated with ACO. Patients and Methods: 397 adults (age 40– 90 years) were recruited from two Colombian cities: asthma (n=123), COPD (n=100), ACO (n=74) and healthy control (HC, n=100). Plasma protein levels were measured using the Proximity Extension Assay (Olink Proteomics). Results: There were no differences in blood eosinophil counts between the patient groups. Total and specified IgE levels were higher in patients with ACO than in those with COPD. Ten plasma proteins showed significant differences between the patients with ACO and HC. In patients above 60 years old, CXCL9 discriminates ACO from asthma patients with AUC 0.73 (0.63– 0.82, DeLong test p=0.007), and in patients below 60 years old, MCP-3 discriminates ACO from COPD patients with AUC 0.84 (0.62– 1.0, DeLong test p=0.006). CUB domain-containing protein 1 (CDCP1) levels (OR, 0.47; p=0.008) and age > 60 years (OR, 0.25; p=0.001) were negatively associated with ACO. Conclusion: CXCL9 levels could be used to discriminate ACO from asthma patients and MCP-3 to discriminate ACO from COPD. Protein inflammatory signatures in plasma of ACO patients were similar to the COPD group. This study revealed novel biomarkers that may help characterize patients with ACO.
- Open Access
- 25 January 2025
- Published by Wiley
Functional Impairment in Oscillometry in Patients with Bronchopulmonary Dysplasia Under 5 Years of Age: A Study in Children Living at High Altitude
Introduction: Patients with bronchopulmonary dysplasia (BPD) exhibit significantly reduced lung function compared to healthy children. However, due to the challenges of performing spirometry in children under 5 years, functional behavior remains poorly characterized, and the utility of impulse oscillometry (IOS) in this population, particularly at high altitude, is unknown. Objective: To compare IOS variables between pediatric patients under 5 years of age with a history of BPD and healthy children residing in a high-altitude city. Methods: This retrospective, analytical, cross-sectional study included pediatric patients aged 3 to 5 years with a history of BPD, evaluated between 2019 and 2023 in Bogotá, Colombia. Healthy children of the same age and sex, previously included in a study of IOS reference values at our institution, were used as controls. Results: A total of 111 patients were included, 71 (64%) with BPD. The mean gestational age in the BPD group was 31 weeks (IQR 28–32 weeks), with a mean birth weight of 1350 grams (IQR 993–1800 grams). Most BPD patients exhibited elevated peripheral airway resistance (84.5%, n=60). Pre-bronchodilator mean values for R5, R20, R5-R20, X5, and AX were significantly higher in the BPD group. Conclusions: Children with BPD have elevated resistance levels and more negative reactance in the airways compared to healthy term children. This study identifies a characteristic functional pattern in children with BPD, which may be defined as an obstructive pattern without bronchodilator response. Longitudinal studies are needed to establish functional trajectories in this population.
- 25 January 2025
- Published by Wiley
Open AccessFunctional Impairment in Oscillometry in Patients with Bronchopulmonary Dysplasia Under 5 Years of Age: A Study in Children Living at High Altitude
Introduction: Patients with bronchopulmonary dysplasia (BPD) exhibit significantly reduced lung function compared to healthy children. However, due to the challenges of performing spirometry in children under 5 years, functional behavior remains poorly characterized, and the utility of impulse oscillometry (IOS) in this population, particularly at high altitude, is unknown. Objective: To compare IOS variables between pediatric patients under 5 years of age with a history of BPD and healthy children residing in a high-altitude city. Methods: This retrospective, analytical, cross-sectional study included pediatric patients aged 3 to 5 years with a history of BPD, evaluated between 2019 and 2023 in Bogotá, Colombia. Healthy children of the same age and sex, previously included in a study of IOS reference values at our institution, were used as controls. Results: A total of 111 patients were included, 71 (64%) with BPD. The mean gestational age in the BPD group was 31 weeks (IQR 28–32 weeks), with a mean birth weight of 1350 grams (IQR 993–1800 grams). Most BPD patients exhibited elevated peripheral airway resistance (84.5%, n=60). Pre-bronchodilator mean values for R5, R20, R5-R20, X5, and AX were significantly higher in the BPD group. Conclusions: Children with BPD have elevated resistance levels and more negative reactance in the airways compared to healthy term children. This study identifies a characteristic functional pattern in children with BPD, which may be defined as an obstructive pattern without bronchodilator response. Longitudinal studies are needed to establish functional trajectories in this population.